In a recent clinical trial by DeCensi et al. (2011), lapatinib was administered to 60 women with erbB-2/Her2+ ductal carcinoma in situ (DCIS) for 3 weeks between the diagnostic biopsy and surgery [34]. This evidence concerns the gene ERBB2 and ductal breast carcinoma in situ.